Legend Biotech Corporation
HealthcareNASDAQ:LEGN · NASDAQ Global Select
-$0.26 today
Vol 1.70M · Avg 2.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-29.6%
avg -13.1%
ROIC
-9.6%
avg -23.0%
ROA
-17.1%
avg -21.6%
Analysis
ROIC is currently the strongest return metric at -9.6% versus its period average of -23.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Birk Vanderweeen | Senior Vice President of Global Manufacturing & Supply | — | — | — | — | — |
Carlos Santos | Chief Financial Officer | — | — | 54 | $0.00 | <0.01% |
Joanne Choi | Senior Manager of Investor Relations | — | — | — | — | — |
Surabhi Verma | Manager of Investor Relations & Corporate Communications | — | — | — | — | — |
Jessie Yeung | Vice President of Finance, Investor & Public Relations | — | — | 41 | — | — |
James Pepin | General Counsel | — | — | — | — | — |
Ananda Elizabeth Martin | Global Compliance Officer | — | — | 52 | — | — |
Guowei Fang | President of Research & Development | — | — | — | — | — |
Ying Huang | Chief Executive Officer & Director | — | — | 53 | $247,438.00 | 0.13% |
Alan Bash | President of CARVYKTI® | — | — | 54 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$87,138.72
Net Sentiment
$87,138.72
Net selling
Most Active
Huang Ying
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $87,138.72 over the last 12 months. That adds up to net selling of $87,138.72. Huang Ying was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +11.9% | +51.1% (9yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +11.9% over three years. Forward estimates point to Revenue at +51.1% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.33B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.28B
Celcuity Inc.
NASDAQ:CELC
$4.33B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.12B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.80B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.66B
Disc Medicine, Inc.
NASDAQ:IRON
$2.61B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Ascentage Pharma Group International
NASDAQ:AAPG
$414.85M
Who manages LEGN?
Legend Biotech Corporation (LEGN) lists 10 active executives. The top listed executive is Birk Vanderweeen, Senior Vice President of Global Manufacturing & Supply.
Are LEGN insiders buying or selling?
Recent insider activity shows net selling of $87,138.72.
Explore More
Continue the stock analysis
Jump to another research area for this company.